LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Atherogenic LDL particles are physicochemically and metabolically heterogeneous. Can bioactive lipid cargo differentiate LDL subclasses, and thus potential atherogenicity? What is the effect of statin treatment? Obese hypertriglyceridemic hypercholesterolemic males [n = 12; lipoprotein (a) <10 mg/dl] received pitavastatin calcium (4 mg/day) for 180 days in a single-phase unblinded study. The lipidomic profiles (23 lipid classes) of five LDL subclasses fractionated from baseline and post-statin plasmas were determined by LC-MS. At baseline and on statin treatment, very small dense LDL (LDL5) was preferentially enriched (up to 3-fold) in specific lysophospholipids {LPC, lysophosphatidylinositol (LPI), lysoalkylphosphatidylcholine [LPC(O)]; 9, 0.2, and 0.14 mol per mole of apoB, respectively; all P < 0.001 vs. LDL1-4}, suggesting elevated inflammatory potential per particle. In contrast, lysophosphatidylethanolamine was uniformly distributed among LDL subclasses. Statin treatment markedly reduced absolute plasma concentrations of all LDL subclasses (up to 33.5%), including LPC, LPI, and LPC(O) contents (up to −52%), consistent with reduction in cardiovascular risk. Despite such reductions, lipotoxic ceramide load per particle in LDL1-5 (1.5–3 mol per mole of apoB; 3–7 mmol per mole of PC) was either conserved or elevated. Bioactive lipids may constitute biomarkers for the cardiometabolic risk associated with specific LDL subclasses in atherogenic dyslipidemia at baseline, and with residual risk on statin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 2 Molar ratios of individual lipid classes normal -ized to moles of apoB in plasma VLDL+IDL, LDL1, LDL2, LDL3, LDL4, and LDL5 subfractions from obese mixed dyslipidemic male MetS subjects at baseline (D0) and after pitavastatin calcium treatment [4 mg/day for 180 days (D180)]. Values are expressed as mean ± SEM (n = 12) in picomoles of each lipid class per picomole of apoB. Percent change (%) was calculated relative to baseline values. *** P < 0.001; **0.001 < P < 0.01; and *0.01 < P < 0.05 versus D0. Density ranges: VLDL+IDL <1.019 g/ml, LDL1 = 1.019-1.023 g/ml, LDL2 = 1.0231.029 g/ml, LDL3 = 1.029-1.039 g/ml, LDL4 = 1.0391.050 g/ml, and LDL5 = 1.050-1.063 g/ml. Lines and square symbols in blue represent data at baseline, D0; red lines and triangular symbols represent data following 180 days of pitavastatin treatment (D180). A-V: COH (A); CE (B); TAG (C); DAG (D); SM (E); PC (F); PC(P) (plasmalogen) (G); PC(O) (H); LPC (I); LPC(O) (J); PE (K); PE(P) (plasmalogen) (L); PE(O) (M); LPE (N); PI (O); LPI (P); Cer (Q); dhCer (R); MHC (S); DHC (T); THC (U); GM3 (V).](https://figures.cochat.ai/paper-figures/173b5ccf2f064e91a8f96bfaefbac5cc/ldl-subclass-lipidomics-in-atherogenic-dyslipidemia-effect-of-statin-therapy-on-figure-2.png)



![Fig. 3 Molar ratios of individual lipid classes nor -malized to moles of PC in VLDL+IDL, LDL1, LDL2, LDL3, LDL4, and LDL5 subfractions from obese mixed dyslipidemic male MetS subjects at baseline (D0) and after pitavastatin calcium treatment [4 mg/ day for 180 days (D180)]. Values are expressed as mean ± SEM (n = 12) in femtomoles of lipid class per picomole of PC. Percent change (%) was calculated relative to baseline values (D0). *** P < 0.001; **0.001 < P < 0.01; and *0.01;<; P < 0.05 versus D0. Density ranges: VLDL+IDL <1.019 g/ml, LDL1 = 1.019-1.023 g/ml, LDL2 = 1.023-1.029 g/ml, LDL3 = 1.029-1.039 g/ml, LDL4 = 1.039-1.050 g/ml, and LDL5 = 1.0501.063 g/ml. A-U: COH (A); CE (B); TAG (C); DAG (D); SM (E); PC(P) (plasmalogen) (F); PC(O) (G); LPC (H); LPC(O), lysoalkylphosphtidylcholine (I); PE (J); PE(P) (plasmalogen) (K); PE(O) (L); LPE (M); PI (N); LPI (O); Cer (P); dhCer (Q); MHC (R); DHC (S); THC (T); GM3 (U).](https://figures.cochat.ai/paper-figures/937b40e401b94689ba6c1518122be18b/ldl-subclass-lipidomics-in-atherogenic-dyslipidemia-effect-of-statin-therapy-on-figure-3.png)



![Fig. 4 Lp-PLA2 activity and mass across VLDL+IDL and LDL1-5 subfractions as a function of density at baseline and effect of pitavastatin calcium treatment [4 mg/day for 180 days (D180)]. Lipoprotein subfractions were isolated from plasma as indicated in the Materials and Methods section, and LpPLA2 mass (expressed as nanograms per milliliter; n = 3; for all data points for apoB-containing lipoproteins at D0 and D180, the mean value for SEM was 6.1 IU/l) and activity (expressed as IU/l; n = 4; for all data points for apoB-containing lipoproteins at D0 and D180, the mean value for SEM was 2.8 IU/l; see the Materials and Methods). Blue line and blue diamond symbols, Lp-PLA2 mass at D0; red line and red square symbols, Lp-PLA2 mass at D180; green line and green triangular symbols, Lp-PLA2 activity at D0, and violet line and violet cross symbols, Lp-PLA2 activity at D180.](https://figures.cochat.ai/paper-figures/1856e01aa1d4454fb7c8af19e5533703/ldl-subclass-lipidomics-in-atherogenic-dyslipidemia-effect-of-statin-therapy-on-figure-4.png)
![Fig. 5 Arterial entry and retention of vsdLDL5: relevance to atherogenesis. The small particle size of vsdLDL particles (LDL5) favors en -hanced arterial wall entry by endothelial transcytosis (13, 21, 51). These particles are preferentially enriched in three bioactive lysophospho -lipids: LPC, 9 mol per LDL5 particle; LPC(O), i.e., lyso-PAF, 1 mol per seven LDL5 particles; and LPI, 1 mol per six LDL5 particles, and equally in Lp-PLA2. sdLDLs display elevated binding affinity for proteoglycan components of the extracellular matrix, favoring enhanced intimal retention (21). Complexes of dense LDL5 particles with proteoglycans (PG) and glycosaminoglycans (GAG) are avidly taken up by human monocyte-derived macrophages (HMDMs) (52). Systemic oxidative stress is a characteristic of dyslipidemic MetS subjects (53); LDL5 lipids are highly susceptible to oxidative modification (21). Oxidative modification leads to scavenger receptor uptake in HMDMs with con -version to pro-inflammatory prothrombotic foam cells, key components of atherosclerotic plaques (1, 21). Hydrophilic lysophospholipids [LPC, LPC(O), LPI] may diffuse out from LDL5 particles into the aqueous phase in arterial tissue. LPC can exert a spectrum of biological effects via two pathways: the indirect pathway involving autotaxin-mediated hydrolysis of LPC with formation of lysophosphatidic acid (LPA), a potent cell signaling mediator acting through multiple G-coupled receptors (32, 54); and the direct pathway involving i ) stimulation of biglycan expression and PG-chain elongation in vascular smooth muscle cells (VSMCs) with induction of an osteogenic phenotype in these same cells (55, 56), ii ) stimulation of monocyte chemoattractant protein-1 (MCP-1) expression in both VSMCs and vascular endothelial cells (ECs) (32), iii ) stimulation of VSMC migration (32), iv ) induction of adhesion protein expression in ECs and VSMCs (32), v ) stimulation of release of arachidonic acid from ECs via the PKC pathway (32), and vi ) induction of the production of IL-1 in HMDMs (57). Together these effects of LDL5-associated LPC indicate a key role for these particles in the acute and chronic inflammatory dimensions of atherogenesis (21, 32, 55, 58). By contrast, LPC suppresses tissue factor expression in human monocytes (59). The degree to which LDL5-associated lyso-PAF may be transformed to active pro-inflammatory PAF depends largely on the potential for its acylation by HMDMs in situ (60). Finally, the LPI/GPR55 axis may initiate a wide range of cellular responses, including cytokine and chemokine secretion, cell proliferation and migra -tion, and platelet aggregation (61, 62). Considered together, these findings indicate that the enhanced intimal entry, retention, and oxida -tion of lysophospholipid-laden LDL5 particles may exert a spectrum of biological actions in arterial tissue, which together favor accelerated atherogenesis in dyslipidemic individuals.](https://figures.cochat.ai/paper-figures/dc4132514c9f4f36afb697866dbf2153/ldl-subclass-lipidomics-in-atherogenic-dyslipidemia-effect-of-statin-therapy-on-figure-5.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Variants in the LpL gene that cause partial LOF of the LpL enzyme, or in other genes affecting LpL activity, also lower the rate of TG removal from VLDL and chylomicrons, resulting in elevated plasma TG levels and remnant accumulation even when TRL secretion is normal (Figure 5).5,44,66”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597 · cited 1×
“Details of the clinical protocol, cohort of MetS subjects, inclusion and exclusion criteria, dietary counseling, and compliance are detailed in the supplemental data and have been reported previously (22, 37, 40, 41, 45).”
MethodGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Self-citationFerence, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638 · cited 2×
“cell interface and in cell signaling cascades (61).”
BackgroundBorén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Self-citationPleiotropic Effects of Statins on the Cardiovascular System
Oesterle, A., Laufs, U., & Liao, J. K. (2017) · Circulation Research · doi:10.1161/circresaha.116.308537 · Cited by 1,247
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233 · cited 2×
“cardiovascular risk in prediabetic MetS subjects and in type 2 diabetes, and reduce levels of all LDL subclasses, including sdLDL, by 30% or more (1, 3, 4, 22, 34, 35).”
BackgroundMetabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896 · cited 1×
“receptor (14, 17, 21), favors accumulation of LPCs in this subclass (19).”
BackgroundLipids and Lipoproteins in Patients With Type 2 Diabetes
Krauss, R. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1496 · Cited by 756 · cited 2×
“ant of sortilin with hepatic lipoprotein production and elevated sdLDL levels (18, 69).”
BackgroundLaaksonen, R., Ekroos, K., Sysi-Aho, M., Hilvo, M., Vihervaara, T., Kauhanen, D., Suoniemi, M., Hurme, R., März, W., Scharnagl, H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw148 · Cited by 674 · cited 3×
“in the pathophysiology of atherosclerosis (9, 29).”
BackgroundCeramides – Lipotoxic Inducers of Metabolic Disorders
Chaurasia, B., & Summers, S. A. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.07.006 · Cited by 616 · cited 3×
“in the pathophysiology of atherosclerosis (9, 29).”
BackgroundChapman, M. J., Goldstein, S., Lagrange, D., & Laplaud, P. M. (1981) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35376-1 · Cited by 553
Self-citationStructure of apolipoprotein B-100 in low density lipoproteins
Segrest, J. P., Jones, M. K., De Loof, H., & Dashti, N. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30267-4 · Cited by 522
Hansel, B., Giral, P., Nobecourt, E., Chantepie, S., Bruckert, E., Chapman, M. J., & Kontush, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0305 · Cited by 477 · cited 1×
“Systemic oxidative stress is a characteristic of dyslipidemic MetS subjects (53); LDL5 lipids are highly susceptible to oxidative modification (21).”
BackgroundSelf-citationHevonoja, T., Pentikäinen, M. O., Hyvönen, M. T., Kovanen, P. T., & Ala-Korpela, M. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00123-2 · Cited by 436
Sphingolipids and phospholipids in insulin resistance and related metabolic disorders
Meikle, P. J., & Summers, S. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.169 · Cited by 423 · cited 1×
“Furthermore, strong evidence for a proatherogenic role of Cers has been provided from animal models of atherosclerosis; such effects involve several mechanisms, including promotion of lipoprotein transport into the arterial wall, platelet activation, and endothelial dysfunction via uncoupling of NO signaling pathways…”
BackgroundSelf-citationMetabolism and atherogenic disease association of lysophosphatidylcholine
Schmitz, G., & Ruebsaamen, K. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.05.029 · Cited by 357 · cited 2×
“Together these effects of LDL5-associated LPC indicate a key role for these particles in the acute and chronic inflammatory dimensions of atherogenesis (21, 32, 55, 58).”
BackgroundSR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis
Huang, L., Chambliss, K. L., Gao, X., Yuhanna, I. S., Behling-Kelly, E., Bergaya, S., Ahmed, M., Michaely, P., Luby-Phelps, K., Darehshouri, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1140-4 · Cited by 353 · cited 1×
“The small particle size of vsdLDL particles (LDL5) favors enhanced arterial wall entry by endothelial transcytosis (13, 21, 51).”
BackgroundNigon, F., Lesnik, P., Rouis, M., & Chapman, M. (1991) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41629-3 · Cited by 326
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-3826 · Cited by 325
Self-citationPlasmalogens the neglected regulatory and scavenging lipid species
Wallner, S., & Schmitz, G. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.06.008 · Cited by 323 · cited 1×
“potent scavengers of reactive oxygen species due to their vinyl ether bond (30).”
BackgroundPlasma Lipid Profiling Shows Similar Associations with Prediabetes and Type 2 Diabetes
Meikle, P. J., Wong, G., Barlow, C. K., Weir, J. M., Greeve, M. A., MacIntosh, G. L., Almasy, L., Comuzzie, A. G., Mahaney, M. C., Kowalczyk, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074341 · Cited by 308 · cited 4×
“even with correction for multiple comparisons (37, 40, 50).”
BackgroundMethodInfluentialSelf-citationBoon, J., Hoy, A. J., Stark, R., Brown, R. D., Meex, R. C., Henstridge, D. C., Schenk, S., Meikle, P. J., Horowitz, J. F., Kingwell, B. A., et al. (2013) · Diabetes · doi:10.2337/db12-0686 · Cited by 303
Self-citationChapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298
Self-citationLanglois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.287037 · Cited by 260
Self-citationTarasov, K., Ekroos, K., Suoniemi, M., Kauhanen, D., Sylvänne, T., Hurme, R., Gouni-Berthold, I., Berthold, H. K., Kleber, M. E., Laaksonen, R., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2559 · Cited by 251 · cited 1×
“Indeed, this hypothesis is not inconsistent with the effect of statin treatment on the plasma lipidome in MetS and in CAD patients (7, 36, 37).”
BackgroundTaguchi, I., Iimuro, S., Iwata, H., Takashima, H., Abe, M., Amiya, E., Ogawa, T., Ozaki, Y., Sakuma, I., Nakagawa, Y., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032615 · Cited by 243 · cited 1×
“Such findings are entirely consistent with the observed action of pitavastatin calcium in reducing cardiovascular events in the REAL-CAD trial (78).”
ResultApolipoprotein B metabolism and the distribution of VLDL and LDL subfractions
Packard, C. J., Demant, T., Stewart, J. P., Bedford, D., Caslake, M. J., Schwertfeger, G., Bedynek, A., Shepherd, J., & Seidel, D. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32065-4 · Cited by 239
Guerin, M., Lassel, T. S., Le Goff, W., Farnier, M., & Chapman, M. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.1.189 · Cited by 237 · cited 1×
“cardiovascular risk in prediabetic MetS subjects and in type 2 diabetes, and reduce levels of all LDL subclasses, including sdLDL, by 30% or more (1, 3, 4, 22, 34, 35).”
BackgroundSelf-citationHepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism
Strong, A., Ding, Q., Edmondson, A. C., Millar, J. S., Sachs, K. V., Li, X., Kumaravel, A., Wang, M. Y., Ai, D., Guo, L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63563 · Cited by 222 · cited 1×
“ant of sortilin with hepatic lipoprotein production and elevated sdLDL levels (18, 69).”
BackgroundChapman, M. J., Laplaud, P. M., Luc, G., Forgez, P., Bruckert, E., Goulinet, S., & Lagrange, D. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38518-7 · Cited by 216
Self-citationTselepis, A. D., Dentan, C., Karabina, S.-A. P., Chapman, M. J., & Ninio, E. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.10.1764 · Cited by 198
Self-citationDeGorter, M. K., Tirona, R. G., Schwarz, U. I., Choi, Y.-H., Dresser, G. K., Suskin, N., Myers, K., Zou, G., Iwuchukwu, O., Wei, W.-Q., et al. (2013) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.113.000099 · Cited by 195 · cited 1×
“This approach in part limited confounding effects due to differences in statin response emanating from genotypic background (76), and from potential differences in baseline phenotype which”
BackgroundGoulinet, S., & Chapman, M. J. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.4.786 · Cited by 191
Self-citationGonçalves, I., Edsfeldt, A., Ko, N. Y., Grufman, H., Berg, K., Björkbacka, H., Nitulescu, M., Persson, A., Nilsson, M., Prehn, C., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.249854 · Cited by 189 · cited 2×
“Together these effects of LDL5-associated LPC indicate a key role for these particles in the acute and chronic inflammatory dimensions of atherogenesis (21, 32, 55, 58).”
BackgroundSmall Dense LDL Cholesterol and Coronary Heart Disease: Results from the Framingham Offspring Study
Ai, M., Otokozawa, S., Asztalos, B. F., Ito, Y., Nakajima, K., White, C. C., Cupples, L. A., Wilson, P. W., & Schaefer, E. J. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.137489 · Cited by 180
Ruuth, M., Nguyen, S. D., Vihervaara, T., Hilvo, M., Laajala, T. D., Kondadi, P. K., Gisterå, A., Lähteenmäki, H., Kittilä, T., Huusko, J., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy319 · Cited by 180 · cited 2×
“For example, the sphingolipid-rich LDL subpopulation, by virtue of its susceptibility to aggregation, is independently predictive both of ASCVD progression and cardiovascular death in CAD patients (12).”
BackgroundRosenson, R. S., & Stafforini, D. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024190 · Cited by 165 · cited 2×
“by sdLDL, the effect of statin treatment on its mass and activity were determined (23, 24).”
BackgroundCeramide: A common pathway for atherosclerosis?
Bismuth, J. X., Lin, P. H., Yao, Q. C., & Chen, C. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.018 · Cited by 162 · cited 2×
“Indeed, Cers can themselves act as signaling molecules, eliciting target cell responses that include differentiation, proliferation, apoptosis, and inflammation involving production of reactive oxygen species and cytokine gene expression (75).”
BackgroundHurt-Camejo, E., Camejo, G., Rosengren, B., Lopez, F., Wiklund, O., & Bondjers, G. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42610-0 · Cited by 162
Zerrad-Saadi, A., Therond, P., Chantepie, S., Couturier, M., Rye, K.-A., Chapman, M. J., & Kontush, A. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.194555 · Cited by 160 · cited 1×
“It is notable that this methodology facilitates isolation of nondenatured lipoprotein subclasses, with no evidence for either lipid or protein oxidation during the procedure (47).”
BackgroundSelf-citationTsimihodimos, V., Karabina, S.-A. P., Tambaki, A. P., Bairaktari, E., Goudevenos, J. A., Chapman, M. J., Elisaf, M., & Tselepis, A. D. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0202.102918 · Cited by 158 · cited 1×
“dative stress as indicated by reduction in levels of oxLDL, Lp-PLA2, and serum amyloid A, and increment in PON activity; reduction of Lp-PLA2 is a statin class effect (71, 72).”
BackgroundSelf-citationThe composition and metabolism of large and small LDL
Diffenderfer, M. R., & Schaefer, E. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000067 · Cited by 151 · cited 1×
“receptor (14, 17, 21), favors accumulation of LPCs in this subclass (19).”
BackgroundMcNamara, J. R., Small, D. M., Li, Z., & Schaefer, E. J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37557-x · Cited by 147
Lund-Katz, S., Laplaud, P. M., Phillips, M. C., & Chapman, M. J. (1998) · Biochemistry · doi:10.1021/bi980828m · Cited by 143 · cited 1×
“Preparative fractionation of apoB-containing lipoproteins (VLDL+IDL, LDL1-5 subclasses) in the native nonoxidized state was performed by isopycnic density gradient ultracentrifugation (see supplemental data) (14, 15, 22, 23, 46).”
MethodSelf-citationLysophosphatidylcholine induces the production of IL-1β by human monocytes
Liu‐Wu, Y., Hurt‐Camejo, E., & Wiklund, O. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00295-5 · Cited by 137
Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance
Han, M. S., Lim, Y.-M., Quan, W., Kim, J. R., Chung, K. W., Kang, M., Kim, S., Park, S. Y., Han, J.-S., Park, S.-Y., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014787 · Cited by 135 · cited 1×
“Effect of pitavastatin therapy on lysolipids and ceramides 925 Furthermore, LPC acts as an effector of fatty acid-induced insulin resistance (33).”
BackgroundVallejo‐Vaz, A. J., Seshasai, S. R. K., Kurogi, K., Michishita, I., Nozue, T., Sugiyama, S., Tsimikas, S., Yoshida, H., & Ray, K. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.001 · Cited by 134
Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat.
Sekas, G., Patton, G. M., Ec, L., & Robins, S. J. (1985) · PubMed · Cited by 113
Ståhlman, M., Pham, H. T., Adiels, M., Mitchell, T. W., Blanksby, S. J., Fagerberg, B., Ekroos, K., & Borén, J. (2012) · Diabetologia · doi:10.1007/s00125-011-2444-6 · Cited by 107 · cited 2×
“Clearly then, the content of these sphingolipids is preferentially conserved and even elevated as LDL particle numbers diminish and as the molar content of other lipid classes relative to apoB diminishes in parallel with the fall in size and molecular weight (13, 17, 28, 63).”
BackgroundLysophosphatidylinositol signalling: New wine from an old bottle
Piñeiro, R., & Falasca, M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.01.009 · Cited by 103 · cited 2×
“ubiquitous orphan GPR55 receptor, including those underlying inflammation, obesity, and diabetes (62).”
BackgroundNg, T. W., Ooi, E. M. M., Watts, G. F., Chan, D. C., Weir, J. M., Meikle, P. J., & Barrett, P. H. R. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1665 · Cited by 97 · cited 1×
“Indeed, this hypothesis is not inconsistent with the effect of statin treatment on the plasma lipidome in MetS and in CAD patients (7, 36, 37).”
BackgroundSelf-citationCASLAKE, M. J., Stewart, G., Day, S., Daly, E., McTaggart, F., Chapman, M. J., Durrington, P. N., Laggner, P., Mackness, M., Pears, J. S., et al. (2003) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2003.08.025 · Cited by 95 · cited 1×
“Statins, or HMG-CoA reductase inhibitors, constitute first line therapy for marked reduction of LDL-associated cardiovascular risk in prediabetic MetS subjects and in type 2 diabetes, and reduce levels of all LDL subclasses, including sdLDL, by 30% or more (1, 3, 4, 22, 34, 35).”
BackgroundSelf-citationWilliams, P. T., Zhao, X.-Q., Marcovina, S. M., Otvos, J. D., Brown, B. G., & Krauss, R. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.01.034 · Cited by 94 · cited 1×
“dissection of the lipid moiety of lipoprotein particles (9, 12, 13, 27).”
BackgroundThe effect of statin therapy on lipoprotein associated phospholipase A2 levels
Albert, M. A., Glynn, R. J., Wolfert, R. L., & Ridker, P. M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.05.006 · Cited by 91
Ibdah, J. A., Lund-Katz, S., & Phillips, M. C. (1989) · Biochemistry · doi:10.1021/bi00429a029 · Cited by 87 · cited 1×
“Interestingly, both COH and SM favor tighter surface packing in the LDL surface lipid monolayer (67).”
BackgroundPCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
Hilvo, M., Simolin, H., Metso, J., Ruuth, M., Öörni, K., Jauhiainen, M., Laaksonen, R., & Baruch, A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.004 · Cited by 87
Chancharme, L., Thérond, P., Nigon, F., Lepage, S., Couturier, M., & Chapman, M. J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.810 · Cited by 80 · cited 2×
“Furthermore, small dense LDLs in atherogenic dyslipidemia are themselves highly susceptible to oxidative modification under conditions of oxidative stress (21, 48).”
BackgroundSelf-citationMeikle, P. J., Wong, G., Tan, R., Giral, P., Robillard, P., Orsoni, A., Hounslow, N., Magliano, D. J., Shaw, J. E., Curran, J. E., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p061143 · Cited by 65 · cited 19×
“Given the phenotypic homogeneity of our subjects (22, 37) and the consistency of their response to statin treatment (see Fig.”
BackgroundMethodInfluentialSelf-citationShiffman, D., Louie, J. Z., Caulfield, M. P., Nilsson, P. M., Devlin, J. J., & Melander, O. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.07.003 · Cited by 65
Dentan, C., Lesnik, P., Chapman, M. J., & Ninio, E. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.00048.x · Cited by 63
Self-citationCurmi, P. A., Juan, L., & Tedgui, A. (1990) · Circulation Research · doi:10.1161/01.res.66.6.1692 · Cited by 61 · cited 1×
“plasma protein does not accumulate in the arterial intima, in contrast to LDL particles (70).”
BackgroundLysophospholipids in laboratory medicine
Yatomi, Y., Kurano, M., Ikeda, H., Igarashi, K., Kano, K., & Aoki, J. (2018) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.94.025 · Cited by 55 · cited 2×
“naling molecule with action on vascular cell function (54).”
BackgroundVickers, K. C., Castro-Chávez, F., & Morrisett, J. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.005 · Cited by 48
Grammer, T. B., Kleber, M. E., März, W., Silbernagel, G., Siekmeier, R., Wieland, H., Pilz, S., Tomaschitz, A., Koenig, W., & Scharnagl, H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu055 · Cited by 46
Tissue Factor Expression of Human Monocytes Is Suppressed by Lysophosphatidylcholine
Engelmann, B., Zieseniss, S., Brand, K., Page, S., Lentschat, A., Ulmer, A. J., & Gerlach, E. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.1.47 · Cited by 45 · cited 1×
“By contrast, LPC suppresses tissue factor expression in human monocytes (59).”
BackgroundChapman, M. J., Orsoni, A., Robillard, P., Hounslow, N., Sponseller, C. A., & Giral, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.874989 · Cited by 44 · cited 2×
“Details of the clinical protocol, cohort of MetS subjects, inclusion and exclusion criteria, dietary counseling, and compliance are detailed in the supplemental data and have been reported previously (22, 37, 40, 41, 45).”
BackgroundMethodSelf-citationPeroxisome Proliferator-Activated Receptors Mediate Pleiotropic Actions of Statins
Paumelle, R., & Staels, B. (2007) · Circulation Research · doi:10.1161/01.res.0000269334.42814.d2 · Cited by 42
Orsoni, A., Thérond, P., Tan, R., Giral, P., Robillard, P., Kontush, A., Meikle, P. J., & Chapman, M. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p068585 · Cited by 40 · cited 16×
“gov: NCT01595828) consists of a small extensively phenotyped cohort of moderately insulin-resistant obese males with MetS and a mixed dyslipidemia at elevated cardiovascular risk (22, 37, 40, 41).”
BackgroundMethodInfluentialSelf-citationInhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling
Binnington, B., Nguyen, L., Kamani, M., Hossain, D., Marks, D. L., Budani, M., & Lingwood, C. A. (2016) · Glycobiology · doi:10.1093/glycob/cwv084 · Cited by 37
Chang, M. Y., Tsoi, C., Wight, T. N., & Chait, A. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000069208.20268.d0 · Cited by 35 · cited 2×
“Together these effects of LDL5-associated LPC indicate a key role for these particles in the acute and chronic inflammatory dimensions of atherogenesis (21, 32, 55, 58).”
BackgroundEffects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial
Braun, L. R., Feldpausch, M. N., Czerwonka, N., Weiss, J. J., Branch, K. L., Lee, H., Martínez-Salazar, E. L., Torriani, M., Sponseller, C. A., Grinspoon, S. K., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01446 · Cited by 32
Drug‐Placebo Additivity in Randomized Clinical Trials
Hall, K. T., & Loscalzo, J. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1626 · Cited by 25 · cited 1×
“effects in randomized clinical trials have recently been questioned (77).”
BackgroundLuc, G., de Gennes, J.-L., & Chapman, M. J. (1988) · Atherosclerosis · doi:10.1016/0021-9150(88)90138-4 · Cited by 24 · cited 2×
“Clearly then, the content of these sphingolipids is preferentially conserved and even elevated as LDL particle numbers diminish and as the molar content of other lipid classes relative to apoB diminishes in parallel with the fall in size and molecular weight (13, 17, 28, 63).”
BackgroundSelf-citationChapman, M. J., Orsoni, A., Robillard, P., Thérond, P., & Giral, P. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.001 · Cited by 20 · cited 19×
“gov: NCT01595828) consists of a small extensively phenotyped cohort of moderately insulin-resistant obese males with MetS and a mixed dyslipidemia at elevated cardiovascular risk (22, 37, 40, 41).”
BackgroundMethodResultInfluentialSelf-citationPathological phenotypes of LDL particles
Laufs, U., & Weingärtner, O. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy387 · Cited by 17
Chen, Y., Xu, S., & Duan, R. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0137-8 · Cited by 11 · cited 1×
“Effect of pitavastatin therapy on lysolipids and ceramides 927 activity in liver cells is dose-dependently regulated by mevalonate levels; lower mevalonate levels induced by statin action are associated with enhanced SMase activity (74), leading to enhanced Cer formation (74, 75).”
Background
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“In addition, several studies have indicated that TRL ceramide species may be predictive of cardio-vascular events and mortality 66,160–162 ( Box 5 ).”
BackgroundInfluentialSelf-citationApolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 270
“Data are supplied on individual subfractions within apoB-containing particles and the extent of oxidation of phospholipids on apoB particles can be determined [192,272,273].”
BackgroundApolipoprotein B-containing lipoproteins in atherogenesis
Borén, J., Packard, C. J., & Binder, C. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01111-0 · Cited by 120
“This higher atherogenic-ity despite a lower cholesterol content per particle 3,165 is potentially explained by the greater ability of small, dense LDL to bind to artery wall proteoglycans 3,166,167 .”
Dyslipidemia in rheumatoid arthritis: the possible mechanisms
Yan, J., Yang, S., Han, L., Ba, X., Shen, P., Lin, W., Li, T., Zhang, R., Huang, Y., Huang, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254753 · Cited by 114
“Because of this, LDLR is incapable of recognizing sdLDL, making it easier to be absorbed by macrophages and become foam cells, which promotes atherosclerosis development and occurrence (139) (Figure 4).”
BackgroundJin, X., Yang, S., Lu, J., & Wu, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.804214 · Cited by 110
“LDL is cleared after binding to LDL-C receptors, but apoB-100 on the surface of sdLDLC molecules and LDL-C receptors has a low affinity, which makes it difficult for the receptors to recognize sdLDL-C, and is more likely to be absorbed by phagocytes, which develop into foam cells and promote the occurrence and develop…”
Background
Metadata
- Authors
- Chapman, M. J., Orsoni, A., Tan, R., Mellett, N. A., Nguyen, A., Robillard, P., Giral, P., Thérond, P., & Meikle, P. J.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- Université Paris-Saclay (FR)
- Inserm (FR)
- Corresponding author
- Chapman, M. John
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 61
- Issue
- 6
- Pages
- 911-932
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC7269759
- OpenAlex
- W3016440532
- Cited by
- 65
- References
- 80
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 5 · 2023: 11 · 2022: 17 · 2021: 10 · 2020: 2
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 159 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Inserm
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- LDL subclasses, atherogenic dyslipidemia, statin therapy, pitavastatin, bioactive lipids, lysophospholipids, lysophosphatidylinositol, lysophosphatidylethanolamine, ceramide, lipotoxicity, lipoprotein heterogeneity, cardiovascular risk markers
- MeSH terms
- Lipidomics, Female, Humans, Lipoproteins, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.